Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
24 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
Oxford University extends COVID-19 vaccine study to children
13 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
World Health Organization experts provide guidance on use of the Oxford vaccine
11 February 2021
WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.
Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK
5 February 2021
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.
Oxford leads first trial investigating dosing with alternating vaccines
4 February 2021
COVID-19 Clinical Trials Vaccinology
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
26 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine
30 December 2020
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
University spinout PepGen awarded major financing to target Duchenne muscular dystrophy
9 December 2020
Awards & Appointments Neuromuscular Diseases
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Oxford University breakthrough on global COVID-19 vaccine
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Oxford coronavirus vaccine produces strong immune response in older adults
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Evox Therapeutics announces launch of strategic collaboration with the University of Oxford
18 November 2020
Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
SIMON Says…
14 November 2020
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
Children’s pain ‘swept under the carpet for too long’ – Lancet Commission
22 October 2020
Neuroimaging Publication Research
The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.
Paul Riley appointed Director of Oxford’s Institute of Developmental and Regenerative Medicine
11 October 2020
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.
Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show
23 September 2020
Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
Enriching Engagement (Round 2) awardees announced
25 August 2020
Awards & Appointments Neuromuscular Diseases Public Engagement
The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
There is now clear data on Covid-19 and children: it should be safe to reopen English schools
18 August 2020
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Featured publication: Advances in oligonucleotide drug delivery
12 August 2020
Neuromuscular Diseases Publication
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.
Typhoid vaccine project wins Vice-Chancellor award
27 July 2020
Awards & Appointments Vaccinology
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!